Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

  • Healthy Volunteers
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
Trial Identifier:

NCT03959332 YP40902

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT03959332,YP40902 Trial Identifier
      Baloxavir Marboxil Treatments
      Healthy Volunteer Condition
      Official Title

      A Phase I, Single-Centre, Open-Label, Parallel, Two Dose Level Study to Investigate the Pharmacokinetics, Safety, and Tolerability Following a Single Dose of Baloxavir Marboxil in Healthy Chinese Volunteers

      Eligibility Criteria

      All Gender
      ≥20 Years & ≤ 59 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Chinese participants must have Chinese parents and grandparents, all of whom were born in China.
      • Healthy status as defined by absence of evidence of any active or chronic disease
      • Participants whose body weight is ≥50 to <80 kg and body mass index is ≥18.5 to <26 kg/m2
      Exclusion Criteria
      • Participants with a history of stomach, vagus nerve, or intestinal surgery (except for appendectomy)
      • Participants who have a history of allergic symptoms including food allergy (Note: Non-active allergic rhinitis will be allowed)
      • Participants who require chronic drug therapy or those who have used drugs within 3 days prior to screening or within 14 days prior to Day -1
      • Participants who have used alcohol-containing, caffeine-containing, grapefruit containing, or St. John's wort-containing products within 72 hours prior to Day -1
      • Participants who have used tobacco- or nicotine-containing products within 24 weeks prior to screening
      • Participants who have donated > 400 mL of blood within 12 weeks or > 200 mL of blood within 4 weeks prior to screening, or have donated any amount of blood between screening and Day -1

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now